Search the Newsreel

Oncoclinicas (ONCO3) vê prejuízo saltar 234%, para R$ 475 milhões; empresa tem ajustes contábeis 'significativos'

ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of "Moderate Buy" from Analysts

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $4.60, significantly higher than its recent share price of $1.96. The company recently exceeded earnings estimates for the quarter, reporting a loss of …

Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of "Moderate Buy" by Analysts

Analysts have given Pyxis Oncology (NASDAQ:PYXS) a "Moderate Buy" rating, with eight out of ten recommending a buy, one a hold, and one a sell, and an average 12-month price target of $7.50. Recent analyst actions have been mixed, including a downgrade from Wall …

Citius Oncology (NASDAQ:CTOR) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Citius Oncology (NASDAQ:CTOR) reported its quarterly earnings, missing analyst expectations with an EPS loss of $0.08 against an estimated $0.07, and revenue of $1.49 million, below the $2.50 million estimate. Despite the misses, the stock price rose 10% to $0.91 on Friday with double …

Citius Oncology (CTOR) director Jonathan Peri files Form 3 showing no common shares

CG Oncology (CGON) sees Foresite Capital report 4.9% beneficial stake via funds

Foresite Capital funds and James B. Tananbaum have reported beneficial ownership in CG Oncology (CGON) via a SCHEDULE 13G/A filing. While individual funds hold stakes under 5%, James B. Tananbaum, managing member of the involved Foresite Capital entities, is deemed to beneficially own 4,306,174 …

Citius Oncology (CTOR) grows LYMPHIR sales but posts $41M nine-month loss

Kura Oncology (KURA) investors report up to 9.7% beneficial ownership stakes

Montanova Capital, LLC, Averill Master Fund, Ltd., and Aaron Cowen have reported significant beneficial ownership stakes in Kura Oncology, Inc. Montanova Capital and Aaron Cowen each own 9.7% of the common stock, while Averill Master Fund holds 8.8%. The reported shares are directly owned …

Citius Oncology's LYMPHIR has 44 ordering institutions, 383 July vials

Cardiff Oncology (CRDF) asks investors to double authorized common shares

Cardiff Oncology (CRDF) is seeking stockholder approval to significantly increase its authorized capital stock, specifically doubling its common stock from 150 million to 300 million shares. This move aims to provide the company with greater flexibility for future financings, strategic transactions, equity incentives, and …

TCG Crossover group (NASDAQ: ALXO) reports 4.2% ALX Oncology stake in 13G/A

TCG Crossover investment entities and Chen Yu have updated their reported ownership in ALX Oncology Holdings Inc. through an amended Schedule 13G filing. Chen Yu is deemed to beneficially own 4.2% of ALX Oncology's common stock, totaling 5,655,487 shares, through TCG Crossover Fund II, …

Pyxis Oncology (PYXS) CEO receives 250,956-share performance-based option grant

Pyxis Oncology's Interim CEO, Thomas Civik, has been granted a performance-based stock option for 250,956 shares, which vested on August 12, 2026. The option has an exercise price of $1.49 per share and an expiration date of February 3, 2036. This vesting occurred after …

Cullinan Therapeutics, Inc. - Common Stock (CGEM) Stock Price, News, Quote & History

This article provides comprehensive information on Cullinan Therapeutics, Inc. (CGEM), including its current stock price, financial metrics, and a history of recent news and press releases. The company, a biopharmaceutical firm, focuses on developing cancer therapies and has announced several key clinical milestones and …

Kura Oncology (NASDAQ:KURA) Stock Price Up 8% on Analyst Upgrade

Kura Oncology (NASDAQ:KURA) saw its stock price rise 8% following an analyst upgrade from Wedbush, which increased its price target to $38 from $36 while maintaining an "outperform" rating. The company's Q2 results surpassed expectations with a narrower loss and higher revenue, driven by …

A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $23 to $40

This article provides a quick overview of analyst ratings for Kura Oncology (KURA.US), noting a forecast price range of $23 to $40. It indicates that the company is currently receiving a 'Buy' rating from analysts, reflecting positive sentiment. The information is presented as a …

JPMorgan Chase & Co. Has Lowered Expectations for BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Stock Price

Citius Oncology (CTOR) investor reports 9.99% beneficial ownership stake

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 9,353,553 shares of Citius Oncology, Inc. common stock, which represents a 9.99% stake in the company. They hold shared voting and dispositive power over these shares, which are directly held by Armistice …

Kura Oncology FY2029 EPS Cut by Brookline Capital Markets

CG Oncology (CGON): RTW Investments takes 9.7% position, holding 8.5M shares

RTW Investments, LP and Roderick Wong, M.D. have reported a 9.7% beneficial ownership in CG Oncology, Inc. (CGON), totaling 8,514,590 common shares. These shares are held by RTW-managed funds, with RTW Investments and Dr. Wong sharing voting and dispositive power. The ownership percentage is …

ImmuneOnco Sets August Board Meeting to Approve Interim Results and Mull Dividend

CG Oncology's bladder cancer drug shows strong results with 75% response rate and no severe side effects.

CG Oncology's experimental drug cretositimogene grenadenorepvec (cret) has shown promising results in treating non-muscle invasive bladder cancer (NMIBC), achieving a 75% complete response rate and demonstrating a best-in-class safety profile with no severe adverse events. The company plans to submit a Biologics License Application …

CG Oncology Stock: Circling Back After Huge Rally (NASDAQ:CGON)

Pyxis Oncology (NASDAQ:PYXS) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Pyxis Oncology (NASDAQ:PYXS) reported a quarterly loss of $0.40 per share, missing analysts' consensus estimates by $0.06. The stock traded down to $3.01 with a market capitalization of $190.68 million, but analyst sentiment remains a "Moderate Buy" with a $7.50 target price. Institutional investors …

Kura Oncology (KURA) Stock Revenue Growth Clashes With Mounting Losses

CGON (CGON) investor lists 25,989-share sale after series of stock disposals

An investor in CG Oncology, Inc. (CGON) has filed a Form 144, indicating a planned sale of 25,989 common shares with an aggregate market value of $1,973,970.86, expected on August 13, 2026. This filing also discloses a series of prior open-market sales by Ambaw …

Aktis Oncology (NASDAQ:AKTS) Posts Earnings Results, Meets Expectations

Aktis Oncology (NASDAQ:AKTS) recently reported its earnings, meeting the consensus estimate for EPS at ($0.44) and surpassing revenue expectations with $3.38 million. Despite the positive earnings surprise, the stock traded down 0.9% to $23.79, giving the company a market capitalization of approximately $1.27 billion. …

CARDIFF ONCOLOGY, INC. : WILLIAM BLAIR CUTS TO MARKET PERFORM RATING

William Blair has downgraded its rating for Cardiff Oncology, Inc. to Market Perform. This article from Reuters, republished by Webull, indicates a change in analyst sentiment towards the company. Further details on the reasons for the downgrade would require logging in to the Webull …

CG Oncology (CGON): Wellington group discloses 5.3M-share, 6.04% ownership position

A group of affiliated Wellington entities has disclosed a beneficial ownership of 5,324,751 shares of CG Oncology (CGON) common stock, representing 6.04% of the class. This disclosure, filed via a SCHEDULE 13G/A, indicates shared voting power over 4,637,354 shares and shared dispositive power over …

Aktis Oncology (AKTS) builds cash to $517M as losses rise with clinical spend

Aktis Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Aktis Oncology (AKTS) posts Q2 2026 results with $517M cash runway into 2029

Aktis Oncology reported its Q2 2026 results, highlighting progress in its targeted radiopharmaceutical pipeline with promising early data for AKY-2519 and ongoing trials for AKY-1189. The company maintains a strong financial position with $517.3 million in cash, cash equivalents, and marketable securities, projected to …

Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026

Aktis Oncology reported its financial results and business highlights for the second quarter of 2026, showcasing strong execution and progress in its clinical pipeline. The company presented promising first-in-human clinical imaging and dosimetry data for AKY-2519 and is actively enrolling patients in Phase 1b …

Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Cardiff Oncology (CRDF)

Analysts have provided insights on two healthcare companies: Neurogene (NGNE) and Cardiff Oncology (CRDF). Neurogene received a "Strong Buy" consensus with a significant upside, while Cardiff Oncology received a "Moderate Buy" consensus despite a recent downgrade to "Hold" by one analyst.